This study included 699 patients with severe aortic stenosis and high surgical risk of whom 348 received transcatheter aortic valve replacement (TAVR) and 351 received surgery. Previous reports of the results to one, two and three years and this work published simultaneously in Lancet reports the final follow-up at 5 years. The mortality at follow-up<a href="https://solaci.org/en/2015/06/24/partner-to-5-years-tavr-is-an-effective-alternative-to-surgery-in-high-risk-patients/" title="Read more" >...</a>

Previous studies have shown clinical benefits, but also an increased cost to treat patients with symptomatic severe aortic stenosis receiving transcatheter valve replacement (TAVR). There is little consensus regarding the cost-effectiveness for transcatheter versus surgical replacement.&nbsp; The present study was aimed to quantify the quality of life, adjusted survival for quality of life, resource utilization,<a href="https://solaci.org/en/2015/06/24/us-corevalve-cost-effectiveness-of-transcatheter-replacement-versus-surgical-replacement-in-high-risk-patients/" title="Read more" >...</a>

This study evaluated the safety and effectiveness of the CoreValve transcatheter valve replacement in patients with severe aortic stenosis with extreme risk for surgery.&nbsp; The primary end point was a composite of all-cause mortality and stroke at 24 months. The rate of death from any cause or cerebrovascular accident at 24 months was 38% for<a href="https://solaci.org/en/2015/06/24/corevalve-us-pivotal-trial-2-year-results-of-the-self-expanding-valve-on-inoperable-patients/" title="Read more" >...</a>

This study included 358 patients considered inoperable, randomized to TAVR with expandable balloon valve versus conservative treatment. The 5-year end points included all-cause mortality, cardiac mortality, re-hospitalization, and stroke. At 5 years, mortality from all causes was lower in TAVR group versus conservative treatment group (71.8% versus 93.6%, P &lt;0.0001). By dividing patients by STS<a href="https://solaci.org/en/2015/06/24/partner-cohort-b-5-year-results-of-a-balloon-expandable-valve-on-inoperable-patients/" title="Read more" >...</a>

This record has been created in order to evaluate the results of percutaneous aortic valve replacement in the UK and currently includes more than 4500 patients with 100% follow-up for mortality. The 3-year mortality was 61.6 % beyond the device or path. Atrial fibrillation, renal failure, chronic obstructive pulmonary disease and a EuroSCORE &gt; 18.5<a href="https://solaci.org/en/2015/06/24/uk-tavi-registry-long-term-results-of-tavi-in-the-uk/" title="Read more" >...</a>

Severe mitral regurgitation is three times more prevalent than aortic stenosis in the elderly population at high risk and poor prognosis if not treated. Fortis mitral valve was designed using several preclinical models and are now tested for the first time in 4 patients resulting in various technical difficulties and finally the death of 3<a href="https://solaci.org/en/2015/06/24/mitral-first-cases-of-transcatheter-mitral-valve-implantation-tmvi/" title="Read more" >...</a>

The objective of this presentation (n = 1248 p, 43 centers in Europe and Latin America) is to evaluate immediate and long-term results of patients with high risk aortic stenosis classified as inoperable in the &#8220;real world&#8221;.&nbsp; C. Moris2012-05-15

Background: Percutaneous aortic valve implantation (TAVI) is the treatment of choice for patients with severe aortic stenosis considered inoperable according to clinical outcomes at 12 months as reported in the PARTNER study, which demonstrated a reduction in mortality and an improvement in the quality of life for patients. However, the long term benefit of this<a href="https://solaci.org/en/2015/06/24/partner-cohort-b-clinical-events-at-3-years-follow-up-in-patients-with/" title="Read more" >...</a>

The PARTNER Cohort A randomized 699 elderly patients, (mean age 84.1), with severe aortic stenosis for TAVI or conventional surgery in 26 centers. The group of patients who received TAVI was divided into two groups: trans-femoral procedure, (244 patients), or trans-apical procedure, (104 patients). After one year mortality was similar but stroke and transient ischemic<a href="https://solaci.org/en/2015/06/24/partner-cohort-a-at-three-years-the-benefit-continues/" title="Read more" >...</a>

In the PARTNER 1 study, patients with inoperable severe aortic stenosis treated with an aortic valve prosthesis balloon-expandable Edwards-SAPIEN showed a mortality reduction compared with standard treatment. However, the Edwards SAPIEN device is associated with peri-procedural complications. The new generation of Edwards SAPIEN XT prosthesis incorporates significant improvements in the profile of the delivery system,<a href="https://solaci.org/en/2015/06/24/partner-2-edwards-sapien-xt-is-even-better-results-for-partner-ii-cohort-b/" title="Read more" >...</a>